TABLE 6.
Summary of the individual information extracted from each included randomized clinical trial evaluating the effectiveness of probiotics in dairy products on CMD in subjects with metabolic syndrome1
| Study (ref) | Study design, duration (country) | Gender, age (y) | n (I/PL) | ITT | Intervention (IG) (type of admin.—probiotic strain—CFU/d) | Control group | Compared with | WC (cm) | Triglycerides (mg/dL) | Total cholesterol (mmol/L) | LDL cholesterol (mmol/L) | HDL cholesterol (mmol/L) | Fasting glucose (mmol/L) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Added to yogurt matrix | |||||||||||||
| Rezazadeh et al. (64) | R, DB, PC, PG, 8 wk (Iran) | M and W, 20 to 65 | 44 (22/22) | No | Yogurt with Lactobacillus acidophilus La5 (6.45 × 106) and Bifidobacterium lactis BB12 (4.94 × 106) | PL yogurt | End vs BL (IG) | — | — | — | — | — | ↓4.81 |
| Between interv. | — | — | — | — | — | −3.80 | |||||||
| Added to milk matrix | |||||||||||||
| Bernini et al. (65) | R, 45 d (Brazil) | M and W, 18 to 60 | 54 (26/25) | No | Milk with B. lactis subsp. nov. HN019 (3.4 × 108) | Untreated | End vs BL (IG) | P > 0.05 | P > 0.05 | ↓0.39 | ↓0.45 | P > 0.05 | P > 0.05 |
| Between interv. | P > 0.05 | P > 0.05 | −0.55 | −0.40 | P > 0.05 | P > 0.05 | |||||||
n = 2. The difference between interventions was calculated by performing subtraction of the difference between end and baseline of each intervention. (End vs BL) indicated the difference between end and baseline of intervention group. If the result was statistically significant, the difference was shown; if the result was statistically nonsignificant was shown, P > 0.05. admin., administration; BL, baseline; CG, control group; CMD, cardiometabolic disease; DB, double-blind; IG, intervention group; ITT, intention-to-treat; M, men; PC, placebo-controlled; PG, parallel-group; PL, placebo; R, randomized; ref, reference; W, women; —, indicates that the study does not evaluate this parameter.